Chronic myeloid leukemia - some topical issues

被引：10
作者：
Mughal, T. [1 ]
Cortes, J.
Cross, N. C. P.
Donato, N.
Hantschel, O.
Jabbour, E.
Kantarjian, H.
Melo, J. V.
Skorski, T.
Silver, R. T.
Goldman, J. M.
机构：
[1] Univ Texas, SW Med Ctr, Dept Hematol & Stem Cell Transplantat, Dallas, TX 75235 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Southampton, Wessex Reg Genet Lab, Salisbury, Wilts, England
[4] Univ Michigan Hlth Syst, Dept Internal Med, Ann Arbor, MI USA
[5] Austrian Acad Sci, Ctr Mol Med, A-1010 Vienna, Austria
[6] Hammersmith Hosp, Dept Haematol, Imperial Coll, London, England
[7] Temple Univ, Dept Microbiol & Immunol, Philadelphia, PA 19122 USA
[8] Cornell Univ, Weill Med Coll, Presbyterian Hosp, New York, NY USA
来源：
LEUKEMIA | 2007年 / 21卷 / 07期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL; IMATINIB MESYLATE; TYROSINE KINASE; BLAST CRISIS; RESISTANCE; CML; CELLS; INHIBITOR; FTY720;
D O I：
10.1038/sj.leu.2404733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1347 / 1352
页数：6
相关论文
共 44 条
  • [31] BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks
    Nowicki, MO
    Falinski, R
    Koptyra, M
    Slupianek, A
    Stoklosa, T
    Gloc, E
    Nieborowska-Skorska, M
    Blasiak, J
    Skorski, T
    [J]. BLOOD, 2004, 104 (12) : 3746 - 3753
  • [32] Fusion tyrosine kinases: a result and cause of genomic instability
    Penserga, E. T. P.
    Skorski, T.
    [J]. ONCOGENE, 2007, 26 (01) : 11 - 20
  • [33] ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
    Perrotti, D.
    Neviani, P.
    [J]. BRITISH JOURNAL OF CANCER, 2006, 95 (07) : 775 - 781
  • [34] Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells
    Ptasznik, A
    Nakata, Y
    Kalota, A
    Emerson, SG
    Gewirtz, AM
    [J]. NATURE MEDICINE, 2004, 10 (11) : 1187 - 1189
  • [35] In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
    Puttini, Miriam
    Coluccia, Addolorata Maria Luce
    Boschelli, Frank
    Cleris, Loredana
    Marchesi, Edoardo
    Donella-Deana, Arianna
    Ahmed, Shaheen
    Redaelli, Sara
    Piazza, Rocco
    Magistroni, Vera
    Andreoni, Federica
    Scapozza, Leonardo
    Formelli, Franca
    Gambacorti-Passerini, Carlo
    [J]. CANCER RESEARCH, 2006, 66 (23) : 11314 - 11322
  • [36] Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
    Ren, R
    [J]. NATURE REVIEWS CANCER, 2005, 5 (03) : 172 - 183
  • [37] Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia:: historical comparison between two phase 3 trials
    Roy, Lydia
    Guilhot, Joelle
    Krahnke, Tillmann
    Guerci-Bresler, Agnes
    Druker, Brian J.
    Larson, Richard A.
    O'Brien, Steve
    So, Charlene
    Massimini, Giorgio
    Guilhot, Francois
    [J]. BLOOD, 2006, 108 (05) : 1478 - 1484
  • [38] Overriding imatinib resistance with a novel ABL kinase inhibitor
    Shah, NP
    Tran, C
    Lee, FY
    Chen, P
    Norris, D
    Sawyers, CL
    [J]. SCIENCE, 2004, 305 (5682) : 399 - 401
  • [39] BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance
    Slupianek, A
    Schmutte, C
    Tombline, G
    Nieborowska-Skorska, M
    Hoser, G
    Nowicki, MO
    Pierce, AJ
    Fishel, R
    Skorski, T
    [J]. MOLECULAR CELL, 2001, 8 (04) : 795 - 806
  • [40] PROGNOSTIC DISCRIMINATION IN GOOD-RISK CHRONIC GRANULOCYTIC-LEUKEMIA
    SOKAL, JE
    COX, EB
    BACCARANI, M
    TURA, S
    GOMEZ, GA
    ROBERTSON, JE
    TSO, CY
    BRAUN, TJ
    CLARKSON, BD
    CERVANTES, F
    ROZMAN, C
    [J]. BLOOD, 1984, 63 (04) : 789 - 799
12345